Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

InMed Pharmaceuticals (INM) Shares Outstanding (Weighted Average) (2022 - 2025)

InMed Pharmaceuticals' Shares Outstanding (Weighted Average) history spans 4 years, with the latest figure at $4.0 million for Q4 2025.

  • For Q4 2025, Shares Outstanding (Weighted Average) rose 459.7% year-over-year to $4.0 million; the TTM value through Dec 2025 reached $4.0 million, up 459.7%, while the annual FY2025 figure was $975985.0, 156.13% up from the prior year.
  • Shares Outstanding (Weighted Average) reached $4.0 million in Q4 2025 per INM's latest filing, roughly flat from $4.0 million in the prior quarter.
  • In the past five years, Shares Outstanding (Weighted Average) ranged from a high of $4.0 million in Q3 2025 to a low of $166410.0 in Q3 2023.
  • Average Shares Outstanding (Weighted Average) over 4 years is $1.3 million, with a median of $663336.5 recorded in 2024.
  • Peak YoY movement for Shares Outstanding (Weighted Average): tumbled 84.44% in 2024, then skyrocketed 537.7% in 2025.
  • A 4-year view of Shares Outstanding (Weighted Average) shows it stood at $533070.0 in 2022, then dropped by 25.21% to $398673.0 in 2023, then surged by 77.22% to $706546.0 in 2024, then skyrocketed by 459.7% to $4.0 million in 2025.
  • Per Business Quant, the three most recent readings for INM's Shares Outstanding (Weighted Average) are $4.0 million (Q4 2025), $4.0 million (Q3 2025), and $975985.0 (Q2 2025).